Free Trial
NASDAQ:ALVR

AlloVir Q4 2023 Earnings Report

AlloVir logo
$3.08 +0.52 (+20.31%)
As of 08/27/2025

AlloVir EPS Results

Actual EPS
-$12.19
Consensus EPS
-$9.89
Beat/Miss
Missed by -$2.30
One Year Ago EPS
N/A

AlloVir Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AlloVir Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 15, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

AlloVir's Q3 2025 earnings is scheduled for Monday, November 10, 2025, with a conference call scheduled on Tuesday, November 11, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

AlloVir Earnings Headlines

Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
Kalaris Announces Closing of Merger with AlloVir
See More AlloVir Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email.

About AlloVir

AlloVir (NASDAQ:ALVR) engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

View AlloVir Profile

More Earnings Resources from MarketBeat